Core Viewpoint - Beihai Kangcheng-B (01228) reported a significant increase in stock price following its interim results, with a rise of over 12% and a current price of 2.54 HKD, reflecting a trading volume of 10.31 million HKD [1] Financial Performance - The company reported a revenue of 22.248 million HKD for the first half of the year, a decrease of 50.33% year-on-year [1] - The net profit for the period was 59.238 million HKD, a turnaround from a loss of 247 million HKD in the same period last year [1] - Revenue decline was primarily attributed to the strategic focus on rare diseases initiated in 2021, with the termination of the distribution agreement for the product He Li An in Taiwan by the end of 2024 [1] - Excluding the sales of He Li An in Taiwan, the company's revenue decreased by 1.7 million HKD or 6.9% compared to the same period in 2024, mainly due to proactive inventory management and reduced stock of Mai Ruibei in the channels [1] Strategic Developments - In August 2025, Beihai Kangcheng announced a share subscription agreement with Baiyang Pharmaceutical, with Baiyang investing 100 million HKD in the company [1] - The agreement includes an exclusive commercialization service contract, enhancing strategic collaboration between Beihai Kangcheng and Baiyang Pharmaceutical [1] - A subsidiary of Baiyang Pharmaceutical will gain promotional rights for specific products of Beihai Kangcheng in mainland China, Hong Kong, and Macau [1]
北海康成-B绩后涨超12% 公司上半年实现扭亏为盈 近期与百洋医药达成战略合作